Literature DB >> 36186140

Longer Leukocyte Telomere Length Increases the Risk of Atrial Fibrillation: A Mendelian Randomization Study.

Yaozhong Liu1, Yunying Huang1, Chan Liu2, Qiming Liu1.   

Abstract

Entities:  

Year:  2022        PMID: 36186140      PMCID: PMC9466970          DOI: 10.14336/AD.2022.02251

Source DB:  PubMed          Journal:  Aging Dis        ISSN: 2152-5250            Impact factor:   9.968


× No keyword cloud information.
To the Editor, Advanced age is the most critical driving factor for atrial fibrillation (AF) [1]. As a marker for biological aging, telomere shortening is implicated in numerous age-related diseases [2-5]. However, longer telomere length (TL) may also increase the risks of diseases [4, 5]. A few observational studies have investigated the association between TL and the risk of AF [6-9]. These studies provided inconsistent results and were unable to establish causality. Hence, we conducted the two-sample Mendelian randomization (MR) analysis to evaluate the causal role of leukocyte telomere length (LTL) in AF using summary statistics from large-scale genome-wide association studies (GWAS). The GWAS data for LTL was from UK Biobank (UKB), involving 472,174 participants [5]. LTL was measured as the ratio of telomere repeat copy numbers relative to that of a single-copy gene. The genetic variants in the LTL GWAS have been adjusted for age and sex. Single-nucleotide polymorphisms (SNPs) associated with LTL at genome-wide significance (P<5×10-8) were selected. These SNPs were clumped (linkage disequilibrium R2=0.01, >10,000kb) to ascertain independence. If a particular SNP is absent in the outcome GWAS, its proxy SNP (R2>0.8) is considered as a substitution. In the primary analysis, the GWAS data of AF was obtained from Nielsen’s study [10], including 60,620 cases and 970,216 controls. Since the UKB individuals were also involved in the AF GWAS, this may have produced weak instrumental bias due to sample overlap. We conducted the secondary analysis, and the latest FinnGen 2021 AF GWAS (22,068 cases and 116,926 controls) was used as the outcome data. The MR analyses were performed by Two-Sample MR and Mendelian Randomization packages [11, 12]. The study design was approved by the Institutional Committee on Human Research at the Second Xiangya Hospital. Ethical approval was obtained for all original studies. In the main MR analysis (inverse-variance weighted method), longer genetically determined LTL increased risk of AF in Nielsen’s study (odds ratio [OR], 1.083 [95% CI, 1.009-1.164]; P=0.028) and in FinnGen consortium (OR, 1.182 [95% CI, 1.039-1.344]; P=0.011). Sensitivity analyses (MR-Egger and weighted median method) provided less precise estimates but had consistent directions (Fig. 1). There is no directional pleiotropy (P-Egger intercept > 0.05) or reverse causality.
Figure 1.

AF and heart volume associated with genetically determined LTL. Odds ratios are expressed per 1-SD increase in genetically determined LTL. AF, atrial fibrillation; LTL, leukocyte telomere length; LVEDV, indexed left ventricular end-diastolic volume; LVESV, indexed left ventricular end-systolic volume; LAmax, indexed left atrial maximum volume; LAmin, index left atrial minimum volume; CI, confidence interval.

Heart enlargement has been implicated in the development of AF. The Framingham heart study [13] showed that LTL was positively associated with left ventricular mass. The causal relationship between LTL and heart volume was then investigated using the following GWAS summary data: indexed left ventricular end-diastolic volume (LVEDV, n = 36,041), indexed left ventricular end-systolic volume (LVESV, n=36,041) [14], indexed left atrial maximum volume (LAmax, n= 35,658), and index left atrial minimum volume (LAmin, n=35,658) [15]. Our results confirmed that longer LTL had effect on increasing LVEDV (OR, 1.116 [95% CI, 1.053-1.182], P = 0.00019) and LVESV (OR, 1.073 [95% CI, 1.02-1.13], P = 0.007). No significant causality was detected between LTL and left atrial volume. AF and heart volume associated with genetically determined LTL. Odds ratios are expressed per 1-SD increase in genetically determined LTL. AF, atrial fibrillation; LTL, leukocyte telomere length; LVEDV, indexed left ventricular end-diastolic volume; LVESV, indexed left ventricular end-systolic volume; LAmax, indexed left atrial maximum volume; LAmin, index left atrial minimum volume; CI, confidence interval. Longer telomere length is generally considered a protective factor for cardiovascular diseases [3, 4]. However, we found that longer LTL increases the risk of AF. This finding could partly be attributed to the effect of longer LTL on increasing left ventricular volume[13]. Longer LTL probably promoted the proliferation of residual progenitor cells and then contributed to hypertrophy of the left ventricle. Likewise, this phenomenon was supposed to happen in the left atrium, despite the association between LTL and left atrial volume is not significant. Besides, a previous MR study [5] showed that longer LTL increased blood pressure, insulin-like growth factor-1 level, waist-hip ratio, and triglycerides level. These metabolic risk traits may mediate the effect of longer LTL on incident AF. Interestingly, our results could also explain why athletes are more vulnerable to AF since high-density physical activity could increase LTL. Further validation is required. This study has some limitations. First, the results of the MR study could be disturbed by pleiotropy when genetic instruments affect the outcome through other exposure. However, no directional pleiotropy was detected, and sensitivity analyses yielded convincing results. Second, all participants of the GWASs were of European ancestry. Our finding may not apply to other races. Third, we can’t investigate the non-linear relationship between LTL and AF because of lacking individual data of LTL. Our MR study found that longer LTL may increase the risk of AF, suggesting that longer LTL should be regarded as a risk factor of AF instead of a protective one. Further studies are still required to confirm our findings. It would be necessary to determine whether the LTL is associated with the severity of AF.
  15 in total

Review 1.  Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights.

Authors:  Jelena Kornej; Christin S Börschel; Emelia J Benjamin; Renate B Schnabel
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

2.  Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.

Authors:  Jonas B Nielsen; Rosa B Thorolfsdottir; Lars G Fritsche; Wei Zhou; Morten W Skov; Sarah E Graham; Todd J Herron; Shane McCarthy; Ellen M Schmidt; Gardar Sveinbjornsson; Ida Surakka; Michael R Mathis; Masatoshi Yamazaki; Ryan D Crawford; Maiken E Gabrielsen; Anne Heidi Skogholt; Oddgeir L Holmen; Maoxuan Lin; Brooke N Wolford; Rounak Dey; Håvard Dalen; Patrick Sulem; Jonathan H Chung; Joshua D Backman; David O Arnar; Unnur Thorsteinsdottir; Aris Baras; Colm O'Dushlaine; Anders G Holst; Xiaoquan Wen; Whitney Hornsby; Frederick E Dewey; Michael Boehnke; Sachin Kheterpal; Bhramar Mukherjee; Seunggeun Lee; Hyun M Kang; Hilma Holm; Jacob Kitzman; Jordan A Shavit; José Jalife; Chad M Brummett; Tanya M Teslovich; David J Carey; Daniel F Gudbjartsson; Kari Stefansson; Gonçalo R Abecasis; Kristian Hveem; Cristen J Willer
Journal:  Nat Genet       Date:  2018-07-30       Impact factor: 38.330

3.  Telomere length and the risk of atrial fibrillation: insights into the role of biological versus chronological aging.

Authors:  Jason D Roberts; Thomas A Dewland; James Longoria; Annette L Fitzpatrick; Elad Ziv; Donglei Hu; Jue Lin; David V Glidden; Bruce M Psaty; Esteban G Burchard; Elizabeth H Blackburn; Jeffrey E Olgin; Susan R Heckbert; Gregory M Marcus
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-11-08

4.  Association of leukocyte telomere length with echocardiographic left ventricular mass: the Framingham heart study.

Authors:  Ramachandran S Vasan; Serkalem Demissie; Masayuki Kimura; L Adrienne Cupples; Charles White; Jeffrey P Gardner; Xiaogian Cao; Daniel Levy; Emelia J Benjamin; Abraham Aviv
Journal:  Circulation       Date:  2009-09-14       Impact factor: 29.690

5.  Shortened telomere length is associated with paroxysmal atrial fibrillation among cardiovascular patients enrolled in the Intermountain Heart Collaborative Study.

Authors:  John F Carlquist; Stacey Knight; Richard M Cawthon; Viet T Le; T Jared Bunch; Benjamin D Horne; Jeffrey S Rollo; John A Huntinghouse; J Brent Muhlestein; Jeffrey L Anderson
Journal:  Heart Rhythm       Date:  2015-07-29       Impact factor: 6.343

Review 6.  Telomeres and aging.

Authors:  Geraldine Aubert; Peter M Lansdorp
Journal:  Physiol Rev       Date:  2008-04       Impact factor: 37.312

7.  Telomere length and incident atrial fibrillation - data of the PREVEND cohort.

Authors:  Joylene E Siland; Bastiaan Geelhoed; Isabelle C van Gelder; Pim van der Harst; Michiel Rienstra
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

8.  The MR-Base platform supports systematic causal inference across the human phenome.

Authors:  Gibran Hemani; Jie Zheng; Benjamin Elsworth; Tom R Gaunt; Philip C Haycock; Kaitlin H Wade; Valeriia Haberland; Denis Baird; Charles Laurin; Stephen Burgess; Jack Bowden; Ryan Langdon; Vanessa Y Tan; James Yarmolinsky; Hashem A Shihab; Nicholas J Timpson; David M Evans; Caroline Relton; Richard M Martin; George Davey Smith
Journal:  Elife       Date:  2018-05-30       Impact factor: 8.140

Review 9.  Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis.

Authors:  Philip C Haycock; Emma E Heydon; Stephen Kaptoge; Adam S Butterworth; Alex Thompson; Peter Willeit
Journal:  BMJ       Date:  2014-07-08

10.  Genome-wide association study identifies 18 novel loci associated with left atrial volume and function.

Authors:  Gustav Ahlberg; Laura Andreasen; Jonas Ghouse; Litten Bertelsen; Henning Bundgaard; Stig Haunsø; Jesper H Svendsen; Morten S Olesen
Journal:  Eur Heart J       Date:  2021-11-21       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.